Giray Ergin 🩺

Doç.Dr. Üroloji Uzmanı. Assoc. Prof. MD. Urologist. Robotic Surgeon. Koru Ankara Hospital. Askeri Tıbbiyeli 👨‍👧‍👦🥼🩺

[Giray Ergin 🩺 @gerginuro]

@LockScreenNotes Good

[Giray Ergin 🩺 @gerginuro]

@LockScreenNotes Good job 👍🏻

[Giray Ergin 🩺 @gerginuro]

Robotik cerrahide hem hassasiyet hem de çorapta stil şart!Bugün biri robotik radikal prostatektomi, diğeri robotik parsiyel nefrektomi yaptık.3D görüş,hassasiyet,hastaya daha az ağrı,daha hızlı iyileşme sağlar.Bilim, teknoloji ve biraz da renkli çoraplar. hepsi hastalar için!😄🧦

[Giray Ergin 🩺 @gerginuro]

https://t.co/P2iRI1Ee7q

[Giray Ergin 🩺 @gerginuro]

@DrYukselUrun ☺️👍🏻

[Prostate Cancer and Prostatic Diseases @pcan_journal]

1️⃣ 📊 PSA density + mpMRI: New study finds lesion location matters! For PI-RADS 3:
🔹 PZ lesions → risk rises at PSAd ≥0.05
🔹 TZ lesions → risk rises at PSAd ≥0.13
For PI-RADS ≥4 ➡️ risk stays high regardless.
🩺 Read more: [https://t.co/MAVA2QzTHb]

[Diego A. Díaz-García @diegoadiazg]

🔔 Testicular cancer is the most common solid tumor in people with testicles aged 15–44.

A @TheLancet seminar reviews management of seminoma and non-seminoma, follow-up, relapse strategies, and future directions.

DOI 👉🏻 https://t.co/iJjSUsOQXw

#CánCare #oncology #testicularcancer #germcelltumors

[Giray Ergin 🩺 @gerginuro]

@DrYukselUrun 👏🏻👏🏻

[Yüksel Ürün @DrYukselUrun]

A mind-opener review on muscle-invasive bladder cancer. Must-read for GU oncologist.
#BladderCancer #Oncology #Immunotherapy
@MattGalsky @l_ballas @UroDocAsh @ASCO @JCO_ASCO @WorldBladderCan @OncoAlert @OncBrothers @Uromigos @urologysummit
https://t.co/5m8oCfZqnd

[Yüksel Ürün @DrYukselUrun]

Exercizumab is real.
Aerobic exercise cut colon cancer recurrence + death.
It’s time to combine movement with medicine not one or the other.
#oncology #Cancer @NEJM @OncoAlert @ASCO #ASCO25
DOI: 10.1056/NEJMoa2502760

[Beşiktaş JK @Besiktas]

#LetTheGameBegin

[European Association of Urology (EAU) @Uroweb]

NEW: The EAU Guidelines Bot
The right answers, seconds away

Ask personalised treatment questions and receive instant answers based on the EAU Guidelines.
Available in each topic section of the EAU Guidelines.

Try it today via the Guidelines page: https://t.co/SmUgAEcPnQ

[UroToday.com @urotoday]

#ACCEL trial tests actinium-225-PSMA-62 in #ProstateCancer. @Ramysaleh86 @RIMUHC1 joins @neerajaiims @huntsmancancer to discuss on UroToday. Early results show reduced xerostomia & minimal toxicity—potentially expanding radioligand options beyond Lu-177. #FullVideo > https://t.co/vajcU4bOzF

[European Association of Urology (EAU) @Uroweb]

🧾 New Cheat Sheet on Prostate Cancer Treatment by Stage

🔹 Low-risk: Active surveillance; avoid ADT
🔹 Intermediate-risk: Surgery or RT; ADT case-based
🔹 High-risk: Surgery/RT + long-term ADT

#EAUguidelines #ProstateCancer

Download Cheat Sheet here:
https://t.co/IvTGHuFWt6

[UroToday.com @urotoday]

🚨 @FDA approves #Darolutamide
Darolutamide (#Nubeqa) is now approved for metastatic castration-sensitive prostate cancer #mCSPC as monotherapy! 🧬

Approval backed by data from the #ARANOTE trial showing significant rPFS benefit. #ProstateCancer #GUonc #FDA
#ReadNow details on UroToday > https://t.co/1xw7kvZ8YZ @BayerPharma

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Congrats @AarmstrongDuke for the 5-yr follow-up OS results from ph3 Arches trial in mHSPC #prostatecancer with enzalutamide @ASCO #ASCO25 👉66% probability of survival at 5 yrs & 30% reduction of risk of death with enzalutamide👇@OncoAlert @urotoday @PCF_Science @AzadOncology

[UroToday.com @urotoday]

Long-term results of N-803 + BCG for BCG-unresponsive #BladderCancer. @UroCancerMD @VUMCurology joins @zklaassen_md @GACancerCenter to discuss updates on N-803, long-term data with median follow-up now exceeding 2.5 years, showing a complete response rate of 71% in the CIS population. #WatchNow > https://t.co/fGVpyNFw0q

[Burak Somkaya @BurakSomkaya]

En düşük puanla alan 13 bölüm direkt hayati bölümler!!!

Arada 1 boşluk bıraktıktan sonraki 2 bölüm daha hayati branşlar!!!

İlk 25 bölüm ise hasta görmeyen branşlardan oluşuyor. Yani Doktorlar artık sınava, hasta bakmamak için çalışıyor!!

Belediye İşçisi ile Doktoru eşitlemenin sonuçları!!!!

[Giray Ergin 🩺 @gerginuro]

Prostat kanseri tedavisinde ameliyatsız tedavi imkanı Robotik HiFU tedavisi ile hastalar aynı gün taburcu #focalone #hifu

[European Urology @EUplatinum]

Review - Testis Cancer: Epidemiology and Risk Factors for Testicular Cancer: A Systematic Review by @vale_tateo et al
Read the full article here: https://t.co/kOI7SqJM1z
Watch all our Spotlights here: https://t.co/eQczkyIlQV

#UroSoMe #MedTwitter #EditorsChoice #TestisCancer #EurUrol #SpotlightArticle